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Salt Lake City, Utah
Clinical expertise and technology have facilitated the use of
Homo sapiens in molecular genetics. In this issue of the
Journal of
the American College of Cardiology, molecular
genetics has begun to return the favor to clinical medicine
(1).
Echocardiography helped solve many of the mysteries
surrounding hypertrophic cardiomyopathy . Using M-mode,
two-dimensional, and Doppler echocardiography, investiga-
tors described the anatomy, physiology and natural history
of this disorder, insights that taught us much about the
pathogenesis of disease. We now know, for example . that
symptoms of hypertrophic cardiomyopathy result from both
diastolic and systolic dysfunction . Diastolic dysfunction is
presumably caused by a thickened, noncompliant ventricle,
whereas systolic dysfunction results from both fixed and
dynamic obstruction to left ventricular outflow . Population-
based studies taught us that the severity and morphology of
hypertrophic cardiomyopathy are quite variable from one
patient to another. Sequential echocardiographic studies
demonstrated that the disease is dynamic and that children
with mild disease are still at risk for life-threatening illness
later in life . Echocardiography's novel insight into hypertro-
phie cardiomyopathy even led to new descriptive terms like
asymmetric septal hypertrophy (ASH) and systolic anterior
motion of the mitral valve (SAM). terms that are now
synonymous with the disease .
Echocardiography also taught us that some forms of
hypertrophic cardlomyopathy are familial . Careful compar-
ison of data obtained from relatives of persons with hyper
tropluc cardiomyopathy showed that this disorder could be
inherited as an autosomal dominant trait . Implicit in this
finding was the hypothesis that hypertrophic cardiomyopa
thy was caused by the inheritance of a single, identifiable
gone. Over the last 4 years, this hypothesis has been tested
by molecular genetics .
In the 1980s it became possible to identify the chromo-
somal location of disease genes using linkage analysis . The
premise underlying linkage analysis is that two genes located
on the same chromosome are physically linked and will be
inherited together from generation to generation . By con-
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trast, genes that are located on distinct chromosomes will be
inherited independently. Linkage analysis is an attempt to
identify genes that are co-inherited more frequently than
would be expected by chance and are therefore likely to be
located on the same chromosomal subunit .
The fist step in linkage analysis is to accurately define the
phenotype, or physical appearance, with respect to hyper-
tro,hic cardiomyopathy of every member of a family . To
identify the chromosomal location of a gene causing hyper-
trophic cardiomyopathy, one must identify a polymorphic
deoxyribonucleic acid (DNA) marker that is always, or
nearly always, co-inherited with the disease phenotype . As
linkage analysis is based on a comparison of genotype and
phenotype, accurate phenotypic classification is critical to
the success of the endeavor. This process can be extremely
challenging, particularly for disorders like hypertrophic car-
diomyopathy that show considerable phenotypic variability .
Fortunately, echocardiography met the challenge and in
1989, Jarcho et al. (2) mapped a gene for familial hypertro-
phic cardiomyopathy to the long arm of chromosome 14 .
This initial discovery made genetic testing for this disorder
feasible in some families and soon led to the identification of
a disease gene. A candidate gene, the beta cardiac myosin
heavy chain gene, was already localized to the same chro-
mosomal subunit as the polymorphic DNA markers that
defined linkage .
The identification of a candidate gene was fortunate . The
alternate approach to disease gene identification, often re-
ferred to as positional cloning or mapping and mutational
analysis, can be much slower than the pace of discovery we
have enjoyed with hypertrophic cardiomyopathy . Over the
last 3 years, investigators identified nine different mutations
of the beta cardiac myosin heavy chain gene that cosegre-
gated with the disease in families, supporting the hypothesis
that these mutations caused hypertrophic cardiomyopathy in
these families (3-6). The identification of de nova mutations
in this gene proved the point (7) .
Myosin is a complex multi-subunit protein that is critical
for myofibrillar contraction in eukaryotes. Each molecule of
myosin consists of six polypeptides, two identical heavy
chains and two pairs of light chains (8,9) . The globular head
of the myosin heavy chain subunits contains both the ade-
nosine triphosphate and actin-binding domains that are es-
sential for the generation of force . Nearly all of the myosin
mutations identified in hypertrophic cardiomyopathy thus
far are point mutations causing single amino acid substitu-
tions in the head or head-rod junction. Although the precise
role of these amino acids is uncertain, each has been highly
conserved during evolution, suggesting that these residues
are important for myofibrillar assembly and function . These
observations have led to speculation that the clinical and
pathologic features of hypertrophic cardiomyopathy (ven-
tricular hypertrophy, myocel ular disarray and myocardial
scarring) are secondary phenomena resulting from abnormal
myofibrillar assembly and reduced force generation . In this
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hypothesis, abnormal beta cardiac myosin heavy chain pro-
tein interferes with normal myofibrillar assembly by inter-
acting with normal myofibrillar proteins .
Cuda et al . (10) recently identified biochemical evidence
supporting this hypothesis . These investigators used myosin
antibodies to partially purify aberrant myosin from the
soleus muscle of affected persons . They used this abnormal
myosin in an in vitro assay that measured the rate of sliding
of rhodamine phalloidin-labeled actin filaments translocated
by myosin molecules bound to nitrocellulose . These studies
showed that myosin molecules purified from persons carry-
ing two different hypertrophic cardiomyopathy mutations
(908 Leu-Val and 403 Arg-61n) translocated actin filaments
at a dramatically reduced rate . These observations are
consistent with the hypothesis that abnormal myosin func-
tion can cause hypertrophic cardiomyopathy .
In this issue of the Journal, Solomon et al . (1) describe
their t .se of the tools of molecular genetics to revisit the
echocardiographic roots of this disorder. These investigators
used echocardiography to study the morphology and extent
of disease in members of families with hypertrophic cardio-
myopathy caused by mutations in the beta cardiac myosin
heavy chain gene . The spectrum of ventricular hypertrophy
and morphology was quite wide and considerable overlap
between the genotypically unaffected and affected groups
became apparent . The maximal left ventricular wall thick-
ness ranged from II to 40 mm in genotypically affected
persons . By comparison, the range of left ventricular wall
thickness in genotypically unaffected persons was 7 to
16 mm. Systolic anterior motion of the mitral valve was
present in 56% of disease gene carriers and was absent in
noncarriers . Finally, 77% of affected persons had a septal to
free wall ratio ~ 1 .3, whereat only 6% of the unaffected
group had a ratio at this level . Thus, echocardiography was
neither completely sensitive nor specific for the diagnosis of
hypertrophic cardiomyopathy .
This is not bad news for echocardiographers or clinicians .
Echocardiography is clearly useful for the diagnosis of
hypertrophic cardiomyopathy in most patients . In those
patients who can not be defined clinically, genetic testing
may solve the ambiguity . This is important because patients
with undiagnosed hypertrophic cardiomyopathy are still at
risk for developing life-threatening disease. Continued corn-
parisons of genotype and echocardiographic phenotype will
facilitate the use of ultrasound in assessing the severity of
disease, risk of sudden death and response to therapy .
Echocardiography and molecular genetics continue to be
complementary in our efforts to understand and alter the
natural history of hypertrophic cardiomyopathy . Recent
studies indicate that this disorder is heterogeneous (11-13) .
Wattkins et al . (14) and Thierfelder et al . (15) identified two
new loci for hypertrophic cardianrtyopathy, one on the long
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arm of chromosome I and the other on the long arm of
chromosome 15. These studies also showed that some fam-
ilies are not linked to chromosome 1, 14, or 15, indicating
that a fourth locus of hypertrophic cardiomyopathy must
exist . Although neither of these new g-l-res has been charac-
terized, with time these studies will undoubtedly reveal
much about myocardial structure and function .
In the final analysis, hypertrophic cardiomyopathy is not
a disease of myosin but a disease of the heart . Continued
collaboration among investigators who examine the heart at
the molecular, cellular and organ levels will be required if we
are to improve our understanding, and prevent the conse-
quences, of this potentially deadly disease .
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